Fujioka, Kazuki
Kasahara, Akiko
Kida, Takashi
Fujii, Wataru
Seno, Takahiro
Wada, Makoto
Kohno, Masataka
Kawahito, Yutaka
Article History
Received: 25 April 2022
Accepted: 3 July 2022
First Online: 11 July 2022
Declarations
:
: This study was approved by the Ethics Committee of Kyoto Prefectural University of Medicine (ERB-C-1044).
: All authors have read and approved the contents of the manuscript, and agreed with publication.
: KF is not considered to have any competing interests related to this study, but declares as a potential competing interest that KF has received research grants from GlaxoSmithKline. WF is not considered to have any competing interests related to this study, but declares as potential competing interests that WF has received research grants from Boehringer Ingelheim, GlaxoSmithKline, and Takeda. YK is not considered to have any competing interests related to this study, but declares as potential competing interests that YK has received research grants from AbbVie, Asahi Kasei, Astellas, Ayumi, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi Tanabe, Pfizer, Takeda, Teijin, GlaxoSmithKline, and Gilead Sciences. The other authors declare that they have no competing interests.